Evelo Biosciences Stock (NASDAQ:EVLO)


OwnershipChart

Previous Close

-

52W Range

- - $0.70

50D Avg

-

200D Avg

$0.02

Market Cap

$28.47K

Avg Vol (3M)

$1.16K

Beta

1.30

Div Yield

-

EVLO Company Profile


Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

66

IPO Date

May 08, 2018

Website

EVLO Performance


Latest Earnings Call Transcripts


Q4 22Mar 16, 23 | 11:24 AM
Q2 22Aug 11, 22 | 11:55 PM
Q4 21Mar 24, 22 | 11:23 AM

Peer Comparison


TickerCompany
NUVBNuvation Bio Inc.
MGTADianthus Therapeutics, Inc.
ENSCEnsysce Biosciences, Inc.
ABVCABVC BioPharma, Inc.
EWTXEdgewise Therapeutics, Inc.
ERASErasca, Inc.
CTMXCytomX Therapeutics, Inc.
GBIOGeneration Bio Co.
SRZNSurrozen, Inc.
APTXAptinyx Inc.
DRMADermata Therapeutics, Inc.
KRONKronos Bio, Inc.
CCCCC4 Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
TPSTTempest Therapeutics, Inc.
PCSAProcessa Pharmaceuticals, Inc.
WINTWindtree Therapeutics, Inc.
NLTXNeurogene Inc.
BXRXBaudax Bio, Inc.
TILInstil Bio, Inc.
ALRNAileron Therapeutics, Inc.